Floatz logo

Belantamab Mafodotin

Monoclonal Gammopathy

Hellenic Society of Hematologyantibody_drug_conjugatePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Monoclonal Gammopathy cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
Liraglutide
University of Miami
Phase 4BB
DOXORUBICIN
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3BB
(+)-VINCRISTINE
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
DARATUMUMAB
Hellenic Society of Hematology
Phase 2B

View all 11 →

Same molecule, other indications

Belantamab Mafodotin is also rated in:

plasma cell myelomaActive
B
Indicative · Phase 3
58 / 100
View asset →
plasma cell neoplasmActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
hematologic disorderActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →